 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
53 News |  |
- || Thelin (oral sitaxsentan) / Pfizer
Trial completion: Sitaxsentan in Proteinuric Chronic Kidney Disease (clinicaltrials.gov) - Feb 4, 2025
P2, N=27, Completed, Sponsor: University of Edinburgh
Unknown status --> Completed
- Comparative Effective Analysis of Treatment for Pulmonary Arterial Hypertension: An Individual Participant Data Network Meta-analysis (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_4495;
Unknown status --> Completed We grouped the individual drugs based on treatment pathways: ambrisentan, bosentan, macitentan, and sitaxsentan were considered
- | Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
Journal: Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report. (Pubmed Central) - Oct 26, 2022
We grouped the individual drugs based on treatment pathways: ambrisentan, bosentan, macitentan, and sitaxsentan were considered A multidisciplinary approach based on clinical evaluation, as well as pharmacological counseling and evaluation of the patient's genetic profile, might be useful for identification of patients with a high chance of drug-induced liver injury, avoiding unnecessary risks in therapy selection and prescription.
- | Thelin (oral sitaxsentan) / Pfizer, Tracleer (bosentan) / J&J, Roche
Biomarker, Enrollment change, Trial withdrawal: Pharmacogenomics in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 9, 2021
P=N/A, N=0, Withdrawn, Sponsor: West Penn Allegheny Health System
A multidisciplinary approach based on clinical evaluation, as well as pharmacological counseling and evaluation of the patient's genetic profile, might be useful for identification of patients with a high chance of drug-induced liver injury, avoiding unnecessary risks in therapy selection and prescription. N=1300 --> 0 | Recruiting --> Withdrawn
- ||| Thelin (sitaxsentan) / Pfizer
3/ ERAs have been tested in HFrEF and in HFpEF: REACH-1, ENABLE 1 & 2, HEAT, EARTH in HFrEF and 1 RCT with sitaxentan in HFpEF. (Twitter) - Dec 25, 2020
- | Thelin (sitaxsentan) / Pfizer
Journal: Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency. (Pubmed Central) - Nov 19, 2020
To conclude, unfavorable reduction in the ETB:ETA protein ratio was observed in two different models of CRI. Therefore, ETA blockade may be beneficial in a range of diseases that cause impaired kidney function.
- || Thelin (sitaxsentan) / Pfizer, Tracleer (bosentan) / J&J, Roche
Clinical, Journal: Liver safety evaluation of endothelin receptor antagonists using HepatoPac : A single model impact assessment on hepatocellular health, function and bile acid disposition. (Pubmed Central) - Oct 16, 2020
Differences across hepatocellular health (cellular adenosine triphosphate/glutathione content), function (urea production/albumin secretion) and taurocholic acid transport (biliary clearance/excretion index) were compared using amiodarone and ciclosporin A as positive controls...Although traditional animal testing provides adequate safety coverage for advancement of novel pharmaceuticals into clinical trials, supplemental assays employing human MPCCs may strengthen weight-of-evidence predictions for sensitive human populations. Proving the predictive value of this single impact assessment model in advance of clinical trial information for human liver injury risk is needed across more pharmaceuticals.
- | Thelin (sitaxsentan) / Pfizer
Preclinical, Journal: Application of a Novel Mass Spectral Data Acquisition Approach to Lipidomic Analysis of Liver Extracts from Sitaxentan-treated Liver-Humanized PXB Mice. (Pubmed Central) - Aug 27, 2020
This method of data generation provides both precursor and fragment ion information, at high specificity, allowing for greater accuracy of compound identification, without the need for spectral libraries. The value of the approach in simplifying and "de-cluttering" the spectra of co-eluting lipids is shown with examples from lipidomic profiles obtained in investigations of the composition of organic extracts of livers obtain from SCID and chimeric liver-humanized mice administered under various experimental conditions.
- | ambrisentan / Generic mfg., Opsumit (macitentan) / Nippon Shinyaku, J&J, Thelin (sitaxsentan) / Pfizer
Journal: Simultaneous quantification of ambrisentan, macitentan and sitaxentan in human plasma by using UPLC-MS/MS. (Pubmed Central) - Apr 1, 2020
The method was successfully validated according to FDA guidelines, to determine the concentration of macitentan, ambrisentan and sitaxentan in human plasma. This method is now being used for study samples and clinical patient samples.
- | Thelin (sitaxsentan) / Pfizer
Journal: Number and brightness analysis to study spatio-temporal distribution of the angiotensin II AT and the endothelin-1 ET receptors: Influence of ligand binding. (Pubmed Central) - Dec 6, 2019
Our results showed that stably transfected angiotensin II AT receptors and transiently transfected endothelin 1 ET receptors, were found as monomeric, dimeric, and tetrameric receptor aggregates. Interestingly, the binding of antihypertensive agents like losartan and BQ123, earlier suggested to be inverse agonists, significantly increased the proportion of monomers and reduced the occurrence of dimers on the cell membrane; while the kown endothelin 1 ET antagonist sitaxentan did not influence the aggregation state of these receptors.
- || Thelin (sitaxsentan) / Pfizer
Clinical, Journal: Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease. (Pubmed Central) - Nov 21, 2019
P2
Twenty-seven subjects with predialysis CKD on optimal cardio- and renoprotective treatment were randomly assigned to receive 6 weeks dosing with placebo, the selective ET receptor antagonist, sitaxentan, or long-acting nifedipine...Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT00810732.
- Thelin (oral sitaxsentan) / Pfizer, Tracleer (bosentan) / J&J, Roche
Trial completion, Trial primary completion date: Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3) (clinicaltrials.gov) - Jul 21, 2015
P0, N=10, Completed, Sponsor: University of Edinburgh
Unique identifier: NCT00810732. Active, not recruiting --> Completed | Trial primary completion date: Sep 2010 --> Sep 2009
- Thelin (oral sitaxsentan) / Pfizer
Enrollment change: Drug Interaction Between Ritonavir And Sitaxsentan (clinicaltrials.gov) - Mar 7, 2015
P1, N=0, Withdrawn, Sponsor: Pfizer
Active, not recruiting --> Completed | Trial primary completion date: Sep 2010 --> Sep 2009 N=18 --> 0
- Thelin (oral sitaxsentan) / Pfizer
Enrollment change: Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan (clinicaltrials.gov) - Mar 7, 2015
P1, N=0, Withdrawn, Sponsor: Pfizer
N=18 --> 0 N=16 --> 0
- ||||||| Thelin (oral sitaxsentan) / Pfizer
Trial completion: Safety and Efficacy Study of Sitaxentan Sodium (Thelin (clinicaltrials.gov) - Feb 22, 2014
P3, N=240, Completed, Sponsor: Encysive Pharmaceuticals
N=16 --> 0 No longer recruiting --> Completed
- Thelin (oral sitaxsentan) / Pfizer
Trial termination: Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma (clinicaltrials.gov) - May 8, 2012
P2, N=17, Terminated, Sponsor: Institut National de la Sant
No longer recruiting --> Completed Recruiting --> Terminated; sitaxentan is not commercialized anymore
- Thelin (oral sitaxsentan) / Pfizer
Enrollment change: Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma (clinicaltrials.gov) - May 8, 2012
P2, N=17, Terminated, Sponsor: Institut National de la Sant
Recruiting --> Terminated; sitaxentan is not commercialized anymore N=50 --> 17
- Thelin (oral sitaxsentan) / Pfizer
Review: Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 2, 2011
P=N/A, N=36, Completed, Sponsor: Pfizer